Alza Corporation

Other

Gurdish K Bhatti

David E Edgren

Howard A Carpenter

Judy A Magruder

Atul D Ayer

Shu W Li

Patrick S-l Wong

Patrick S L Wong

Robert R Skluzacek

Liang-Chang Dong

Si-Hong Yum

Zahedeh Hatamkhani

Brian L Barclay

Patrick SL Wong

A membrane system comprising an interior wall, a fluid-permeable exterior wall surrounding the interior wall and an internal compartment defined by the membrane system, wherein fluid permeability of the interior wall is responsive to osmolarity of an osmotic core within the internal compartment are disclosed. A controlled release dosage form comprising the membrane system and a process for delivering an osmotically active formulation from an osmotic pump over an extended period of time are also disclosed.

Extended release dosage form

The invention pertains to a dosage formand to administering an antidepressant medicamentfor an extended period of time in a rate-known dose.

Antidepressant dosage form

A composition is disclosed comprising a polymer and a surfactant in a solvent exhibiting a common solubility for the polymer and the surfactant. The composition provides a dosage form for administering a drug over time.

Pharmaceutical coating composition and method of use

The invention pertains to a dosage form and to administering an antidepressant medicament for an extended period of time in a rate-known dose.

Method of administering antidepressant dosage form

A dosage form comprising a composition comprising a drug surrounded by an interior and an exterior wall with an exit for administering the drug to a patient; and a method of using the dosage form are disclosed for an indicated therapy.

A dosage form is disclosed comprising an anti-Parkinson's disease drug for administering to a patient in need of anti-Parkinson's disease therapy.

Antiparkinson dosage form

A dosage form is disclosed comprising a wall that surrounds a bilayer core with exit passageway for communicating with the bilayer core in the wall.

Exit means in dosage form

A dosage form is disclosed comprising a first layer and a second layer. The first layer provides immediate therapy and comprises a drug stereoisomer and the second layer provides prolonged therapy and comprises a drug racemate.

Stereoisomer therapy

Dosage form indicated for the management of abnormal posture, tremor and

Dosage form providing immediate therapy followed by prolonged therapy

An osmotic device (10) for delivering a beneficial drug, such as an anti-microbial drug, into the mouth of a human patient is disclosed. The device (10) has a size and shape adapting it to be comfortably retained in the mouth for extended periods of time. The device comprises a thin semipermeable membrane wall (12) surrounding a compartment (13) housing a beneficial agent (14) that has at least some degree of solubility in aqueous biological fluids, e.g., saliva, and a fibrous support material (15) composed of hydrophilic water-insoluble fibers. A passageway (17) in the wall (12) connects the agent 14) with the exterior of the device (10). The wall (12) is permeable to the passage of aqueous biological fluid but substantially impermeable to the passage of the fibrous support material (15). The fibrous support material (15), once hydrated, provides a rigid support for the thin semipermeable wall (12) and prevents the device (10) from prematurely releasing the beneficial agent (14) even when the device (10) is subjected to patient sucking.

Oral osmotic device

Dosage form for treating central nervous system disorders

A dosage form is disclosed comprising a drug and a maltodextrin polymer for administering to a patient a drug in need of therapy.

Growing community of inventors

Fremont, CA, United States of America

Gurdish K Bhatti